By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Dey, L.P. et al. v. Teva Parenteral Medicines, Inc. et al.
1:09-cv-00087; filed June 23, 2009 in the Northern District of West Virginia
• Plaintiffs: Dey, L.P.; Dey, Inc.
• Defendants: Teva Parenteral Medicines, Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.
Infringement of U.S. Patent Nos. 6,667,344 ("Bronchodilating Compositions and Methods," issued December 23, 2003), 6,814,953 (same title, issued November 9, 2004), 7,348,362 ("Bronchodilating β-Angonist Composition and Methods," issued March 25, 2008), and 7,462,645 (same title, issued December 9, 2008) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Dey's Perforomist® (formoterol fumarate inhalation solution, used to treat bronchoconstriction in patients with chronic obstructive pulmonary disease). View the complaint here.
University of Iowa et al. v. Abbott Laboratories et al.
3:09-cv-00099; filed June 22, 2009 in the Southern District of Iowa
• Defendants: Abbott Laboratories; Abbott Bioresearch Center, Inc.; Abbott Biotechnology Ltd.
Infringement of U.S. Patent Nos. 5,168,062 ("Transfer Vectors and Microorganisms Containing Human Cytomegalovirus Immediate-Early Promoter-Regulatory DNA Sequence," issued December 1, 1992) and 5,385,839 (same title, issued January 31, 1995) based on Abbott's manufacture and sale of its Humira® (adalimumab, used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and plaque psoriasis). View the complaint here.
Medicis Pharmaceutical Corp. v. Glenmark Generics Inc., USA et al.
2:09-cv-03010; filed June 16, 2009 in the District Court of New Jersey
• Defendants: Glenamrk Generics Inc., USA; Glenmark Generics Ltd.
Infringement of U.S. Patent Nos. 6,765,001 ("Compositions and Methods for Enhancing Corticosteroid Delivery," issued July 20, 2004) and 7,220,424 (same title, issued May 22, 2007) following a Paragraph IV certification as part of Glenmark's filing of an ANDA to manufacture a generic version of plaintiff's Vanos® (fluocinonide cream, used to relieve inflammation and itching caused by certain skin conditions that respond to corticosteroids). View the complaint here.
Comments